U.S. Mortgage REITs Stock News

Zions Bancorporation, N.A. recently priced and settled a US$500,000,000 fixed‑to‑floating rate senior notes offering due February 9, 2029, with a 4.483% fixed coupon to February 2028 and a subsequent Compounded SOFR plus 1.055% floating rate. The bank plans to use the proceeds to pay down short‑term borrowings while a receive‑fixed hedge converts the new debt cost to floating, reshaping its interest rate risk profile. We’ll now examine how this US$500,000,000 senior notes issuance and...

In February 2026, Leidos Holdings announced a US$0.43 quarterly cash dividend per share, while advancing major defense IT initiatives including accelerating the DODNet migration for over 100,000 users under the US$11.50 billion, 10-year Defense Enclave Services program. Alongside the dividend, Leidos’ recent AI- and cybersecurity-focused contracts and alliances in areas like Zero Trust, automated compliance, and AI governance underscore how its NorthStar 2030 plan is increasingly tied to...

Setting the scene for JPMorgan Chase JPMorgan Chase (JPM) has drawn investor attention recently as its share price, last closing at US$302.55, reflects a mix of short term pullbacks alongside longer term gains in total return. See our latest analysis for JPMorgan Chase. Recent trading has been choppy, with a 7 day share price return of 6.07% decline and a year to date share price return of 7.04% decline. At the same time, the 1 year total shareholder return of 11.63% and 5 year total...

In February 2026, Robinhood Markets, Inc. reported fourth-quarter 2025 revenue of US$1,283 million, up from US$1,014 million a year earlier, while quarterly net income fell to US$605 million from US$916 million, even as the company continued share repurchases and highlighted growth across multiple product lines. Behind the headline miss on revenue expectations, Robinhood underscored that 11 of its products now each generate over US$100 million in annualized revenue, with a forthcoming credit...

Centrus Energy secured a $900 million US government task order to expand uranium enrichment capabilities. The company is shifting toward domestic production of high assay low enriched uranium, or HALEU, for advanced reactors. Centrus entered a new partnership with Fluor to scale operations at its enrichment facility in Ohio. Centrus Energy (NYSE: LEU) sits at the center of a renewed push to build out a domestic nuclear fuel supply, with a current share price of $199.19. The stock has seen...

Newmont (NYSE:NEM) has reached commercial production at its Ahafo North project in Ghana, adding a new producing asset to its portfolio. The company has completed a series of non core asset divestitures, refocusing its portfolio on higher priority operations. Newmont reports record free cash flow alongside elevated gold prices, supporting its plans for capital returns. For investors tracking NYSE:NEM, these updates come with the stock trading at $125.8, with a 1 year return of 174.9% and a...

Galecto, Inc. recently completed a follow-on public offering of common stock, issuing 16,644,737 shares and raising approximately US$316.3 million before fees, with Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities acting as joint book-running managers. Alongside this offering, Galecto filed a mixed shelf registration of up to US$150 million, giving the company additional flexibility to issue various securities over time to support its pipeline in blood cancers and fibrotic...

If you are wondering whether Vertiv Holdings Co is still attractively priced after its run, you are not alone. The stock has become a regular talking point for valuation focused investors. Vertiv's share price closed at US$234.53, with returns of 16.1% over the past week, 32.6% over the past month and 33.6% year to date. The 1 year gain stands at 117.4%, and the 3 year and 5 year returns are very large in percentage terms. Recent coverage around Vertiv has focused on its role in critical...

Klaviyo (NYSE:KVYO) is expanding rapidly in the enterprise market, with a sharp rise in high-value customers. The company is rolling out advanced AI agents that support more autonomous customer experiences. Doubled million dollar ARR accounts and growing enterprise adoption suggest a meaningful shift in its business mix. Klaviyo, known for its marketing automation and customer data platform tools, is pushing further into larger enterprise accounts as retailers and brands seek more automated...

In February 2026, Palomar Holdings reported fourth-quarter and full-year 2025 results showing revenue rising to US$253.36 million for the quarter and US$875.97 million for the year, with net income increasing to US$56.17 million and US$197.07 million respectively, alongside higher basic and diluted earnings per share from continuing operations. Despite these record headline figures, investors focused on weaker-than-expected underwriting efficiency, as margin pressures and a higher combined...

Fourth quarter results and buybacks in focus Marathon Petroleum (MPC) reported fourth quarter 2025 revenue of US$33,422 million with net income of US$1,535 million, alongside continued share repurchases that reduced the share count during the period. See our latest analysis for Marathon Petroleum. The latest quarterly results and ongoing repurchases appear to have supported sentiment, with a 1-month share price return of 15.73% and a year to date share price return of 23.08%. The 5-year total...

On February 16, 2026, Centerspace released its fourth-quarter results, following earlier expectations for an earnings-per-share improvement and upwardly revised revenue forecasts. The earnings release sharpened focus on the trade-off between improving analyst expectations and ongoing balance sheet pressures, including high leverage and low interest coverage. Now, we'll examine how Centerspace's fourth-quarter earnings expectations amid ongoing leverage concerns may influence the company's...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

The nCino, Inc. ( NASDAQ:NCNO ) share price has fared very poorly over the last month, falling by a substantial 33...

Allegion plc's ( NYSE:ALLE ) periodic dividend will be increasing on the 31st of March to $0.55, with investors...

Apollo Global Management, Inc. ( NYSE:APO ) is about to trade ex-dividend in the next 2 days. The ex-dividend date is...

Wondering whether Alvotech at US$4.64 is a potential bargain or a value trap? This article will walk you through what the current price might be implying about the company. The stock has had a tough run, with a 9.7% decline over the last week, 5.7% over the last month and 7.2% year to date, while the 1 year return sits at a 64.3% loss. Recent trading has been shaped by ongoing investor reaction to Alvotech's progress and risks in the biosimilars space, as the market weighs its prospects...

In February 2026, Regal Rexnord reported that fourth-quarter 2025 sales rose to US$1,523.2 million while net income increased to US$63.5 million, with full-year 2025 net income improving to US$279.5 million on slightly lower annual sales of US$5,934.5 million. The company also issued full-year 2026 GAAP diluted EPS guidance of US$5.29 to US$6.09, highlighting management’s confidence after year-over-year earnings growth despite softer annual revenue. With management now guiding 2026 GAAP...

How Walmart (WMT) looks after its recent share performance Recent share price moves have put Walmart (WMT) back on many investors’ screens, with the stock showing positive returns over the past week, month and past 3 months. Here is how the fundamentals compare. See our latest analysis for Walmart. At a share price of US$133.89, Walmart’s recent 30 day share price return of 11.85% and 90 day return of 32.05% point to strong momentum. The 1 year total shareholder return of 29.92%, along with...

If you are wondering whether UiPath is starting to look interesting at current levels, this article will walk through what the recent share price and fundamentals might be telling you about its value. UiPath shares last closed at US$11.32, with returns of 12.9% decline over 7 days, 21.1% decline over 30 days, 28.7% decline year to date, 24.2% decline over 1 year and 27.2% decline over 3 years, which may have shifted how the market is thinking about its risk and potential. Recent headlines...

Abbott Laboratories (ABT) is under fresh legal scrutiny after a wrongful death lawsuit linked alleged defects in its FreeStyle Libre 3 glucose monitors to multiple deaths and serious injuries, drawing investor attention to product safety risk. See our latest analysis for Abbott Laboratories. At a share price of $112.68, Abbott’s recent 1 day and 7 day share price returns of 1.09% and 1.45% sit against a 30 day share price return decline of 7.46% and a 90 day share price return decline of...

Why ADT’s index additions matter for investors ADT (ADT) has just been added to the S&P 600, S&P 1000, S&P Composite 1500, and the S&P 600 Consumer Discretionary index, a shift that can influence trading interest and liquidity. See our latest analysis for ADT. ADT’s recent index additions come after a period where short term share price returns have been soft, with a 7 day share price return decline of 4.56% and a 30 day share price return decline of 6.18%. Meanwhile, the 1 year total...

Boston Scientific (BSX) is back in focus after Q4 2025 adjusted earnings came in above consensus. However, investor attention has shifted to signs of stagnation in the company’s U.S. electrophysiology business. See our latest analysis for Boston Scientific. The share price has retreated sharply in recent months, with a 30 day share price return of 15.15% and a 90 day share price return of 24.68%, even though the 3 year total shareholder return sits at 60.57% and the 5 year total shareholder...

Agios Pharmaceuticals reported full-year 2025 results, with revenue rising to US$54.03 million from US$36.5 million, while swinging from net income of US$673.73 million to a very large net loss of US$412.78 million and filing an omnibus mixed-shelf registration covering equity, debt, warrants, and units. Despite the sharp earnings reversal, investors are focusing on stronger-than-expected quarterly performance, growing contributions from PYRUKYND® and newly launched AQVESME™, and the added...